CRSP - What's Going On With CRISPR Therapeutics Stock? | Benzinga
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target.
What To Know:
On Monday, Morgan Stanley analyst Terence Flynn maintained CRISPR Therapeutics with an Underweight and lowered the price target from $43 to $42.
Last Tuesday, RBC Capital analyst Luca Issi maintains CRISPR ...